ZNF559

Summary

ZNF559 (zinc finger protein 559, HGNC:28197) is a protein-coding gene on chromosome 19p13.2, encoding Zinc finger protein 559 (Q9BR84). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 84527 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 110 total
• MANE Select transcript: NM_032497

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28197
Approved symbol	ZNF559
Name	zinc finger protein 559
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC13105
Ensembl gene	ENSG00000188321
Ensembl biotype	protein_coding
Entrez	84527

Gene structure

Transcript identifiers

Ensembl transcripts: 44 — 44 protein_coding

ENST00000317221, ENST00000393883, ENST00000585352, ENST00000585377, ENST00000586255, ENST00000587557, ENST00000588124, ENST00000589208, ENST00000591652, ENST00000592298, ENST00000592504, ENST00000592896, ENST00000603380, ENST00000605750, ENST00000861660, ENST00000861661, ENST00000861662, ENST00000861663, ENST00000861664, ENST00000861665, ENST00000861666, ENST00000861667, ENST00000861668, ENST00000861669, ENST00000861670, ENST00000861671, ENST00000861672, ENST00000861673, ENST00000861674, ENST00000861675, ENST00000861676, ENST00000861677, ENST00000861678, ENST00000861679, ENST00000861680, ENST00000927122, ENST00000927123, ENST00000927124, ENST00000965257, ENST00000965258, ENST00000965259, ENST00000965260, ENST00000965261, ENST00000965262

RefSeq mRNA: 8 — MANE Select: NM_032497 NM_001202406, NM_001202407, NM_001202408, NM_001202409, NM_001202410, NM_001202411, NM_001202412, NM_032497

CCDS: CCDS12211, CCDS59349, CCDS62531, CCDS62532

Canonical transcript exons

ENST00000603380 — 7 exons

Exon	Start	End
ENSE00003559684	9337796	9337858
ENSE00003560591	9341102	9341184
ENSE00003595962	9324179	9324228
ENSE00003642293	9324695	9324780
ENSE00003661642	9339193	9339319
ENSE00003679825	9338494	9338582
ENSE00003914055	9341695	9345871

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 96.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.7707 / max 143.1427, expressed in 1433 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
173695	5.7707	1433

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	96.91	gold quality
oocyte	CL:0000023	95.41	gold quality
ganglionic eminence	UBERON:0004023	92.62	gold quality
ventricular zone	UBERON:0003053	92.36	gold quality
parietal pleura	UBERON:0002400	91.34	gold quality
calcaneal tendon	UBERON:0003701	91.27	gold quality
left ovary	UBERON:0002119	90.61	gold quality
right ovary	UBERON:0002118	90.40	gold quality
tibia	UBERON:0000979	90.11	gold quality
visceral pleura	UBERON:0002401	90.08	gold quality
ovary	UBERON:0000992	89.69	gold quality
right uterine tube	UBERON:0001302	89.69	gold quality
thymus	UBERON:0002370	89.34	gold quality
pituitary gland	UBERON:0000007	89.26	gold quality
adenohypophysis	UBERON:0002196	89.25	gold quality
smooth muscle tissue	UBERON:0001135	88.87	gold quality
cortical plate	UBERON:0005343	88.87	gold quality
tendon	UBERON:0000043	88.80	gold quality
body of uterus	UBERON:0009853	88.80	gold quality
left ventricle myocardium	UBERON:0006566	88.59	gold quality
endocervix	UBERON:0000458	87.67	gold quality
cardiac muscle of right atrium	UBERON:0003379	87.56	gold quality
myocardium	UBERON:0002349	87.49	gold quality
tendon of biceps brachii	UBERON:0008188	87.45	silver quality
tibial nerve	UBERON:0001323	87.16	gold quality
apex of heart	UBERON:0002098	87.13	gold quality
corpus callosum	UBERON:0002336	86.77	gold quality
spleen	UBERON:0002106	86.76	gold quality
thyroid gland	UBERON:0002046	86.67	gold quality
left lobe of thyroid gland	UBERON:0001120	86.57	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-100618	yes	365.48
E-ANND-3	yes	4.03

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR

miRNA regulators (miRDB)

38 targeting ZNF559, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-6740-3P	99.48	68.49	1392
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-410-3P	99.27	69.98	2457
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-10524-5P	99.05	66.08	963
HSA-MIR-3164	99.02	68.39	1071
HSA-MIR-6820-3P	99.02	68.50	1035
HSA-MIR-1294	98.91	69.26	1030
HSA-MIR-9986	98.91	69.28	1024
HSA-MIR-3145-3P	98.85	69.07	2031
HSA-MIR-384	98.71	67.34	1229

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
drosophila_melanogaster	CG2712	FBGN0024975
drosophila_melanogaster	Phs	FBGN0036522
drosophila_melanogaster	CG3281	FBGN0260741

Paralogs (62): ZNF582 (ENSG00000018869), ZNF264 (ENSG00000083844), ZNF343 (ENSG00000088876), ZNF684 (ENSG00000117010), ZNF133 (ENSG00000125846), ZNF557 (ENSG00000130544), ZNF337 (ENSG00000130684), ZNF20 (ENSG00000132010), ZFP37 (ENSG00000136866), ZNF614 (ENSG00000142556), KRBOX4 (ENSG00000147121), ZNF599 (ENSG00000153896), ZNF19 (ENSG00000157429), ZNF589 (ENSG00000164048), PRDM9 (ENSG00000164256), ZNF180 (ENSG00000167384), ZNF558 (ENSG00000167785), ZNF35 (ENSG00000169981), ZNF778 (ENSG00000170100), ZNF439 (ENSG00000171291), ZNF440 (ENSG00000171295), ZNF556 (ENSG00000172000), ZNF554 (ENSG00000172006), ZNF596 (ENSG00000172748), ZNF80 (ENSG00000174255), ZNF266 (ENSG00000174652), ZNF25 (ENSG00000175395), ZNF77 (ENSG00000175691), ZNF169 (ENSG00000175787), ZNF404 (ENSG00000176222), ZNF491 (ENSG00000177599), ZNF620 (ENSG00000177842), ZNF619 (ENSG00000177873), ZNF875 (ENSG00000181666), ZNF329 (ENSG00000181894), ZFP90 (ENSG00000184939), ZNF566 (ENSG00000186017), ZNF529 (ENSG00000186020), ZNF749 (ENSG00000186230), ZNF555 (ENSG00000186300)

Protein

Protein identifiers

Zinc finger protein 559 — Q9BR84 (reviewed: Q9BR84)

All UniProt accessions (11): A0A0A0MTS4, A0A0A0MTT2, Q9BR84, K7EK98, K7EKU6, K7EM21, K7EN17, K7EQI4, K7ERK9, S4R3F2, S4R3U0

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BR84-1	1	yes
Q9BR84-2	2

RefSeq proteins (8): NP_001189335, NP_001189336, NP_001189337, NP_001189338, NP_001189339, NP_001189340, NP_001189341, NP_115886* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050826	Krueppel_C2H2_ZnFinger	Family

Pfam: PF00096, PF01352

UniProt features (18 total): zinc finger region 13, splice variant 2, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BR84-F1	62.81	0.26

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 106 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, MODULE_256, MODULE_480, GCM_NF2, MODULE_333, MODULE_427, SENESE_HDAC3_TARGETS_DN, chr19p13, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, JOHNSTONE_PARVB_TARGETS_3_DN, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, BANP_TARGET_GENES, CBX5_TARGET_GENES, DYRK1A_TARGET_GENES, HUANG_DASATINIB_SENSITIVITY_UP

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription cis-regulatory region binding	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

642 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF559	ZNF385B	Q569K4	507
ZNF559	ZNF827	Q17R98	493
ZNF559	FAM98C	Q17RN3	473
ZNF559	TSHZ3	Q63HK5	446
ZNF559	ZNF18	P17022	417
ZNF559	ZNF407	Q9C0G0	409
ZNF559	ZNF292	O60281	401
ZNF559	GLIS1	Q8NBF1	394
ZNF559	FEZF1	A0PJY2	377
ZNF559	IQCN	Q9H0B3	370
ZNF559	METTL26	Q96S19	369
ZNF559	ANKRD18A	Q8IVF6	349
ZNF559	TTK	P33981	348
ZNF559	ZBTB20	Q9HC78	347
ZNF559	ZNF774	Q6NX45	342

IntAct

37 interactions, top by confidence:

A	B	Type	Score
MDFI	ZNF559	psi-mi:“MI:0915”(physical association)	0.830
ZNF559	MDFI	psi-mi:“MI:0915”(physical association)	0.830
KRTAP10-5	ZNF559	psi-mi:“MI:0915”(physical association)	0.670
ZNF559	KRTAP10-5	psi-mi:“MI:0915”(physical association)	0.670
ZNF559	KRTAP4-2	psi-mi:“MI:0915”(physical association)	0.560
ZNF559		psi-mi:“MI:0915”(physical association)	0.560
	ZNF559	psi-mi:“MI:0915”(physical association)	0.560
KRTAP4-2	ZNF559	psi-mi:“MI:0915”(physical association)	0.560
CABP5	ZNF559	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-8	ZNF559	psi-mi:“MI:0915”(physical association)	0.560
ZNF559	CARD10	psi-mi:“MI:0915”(physical association)	0.560
MAPK9	ZNF559	psi-mi:“MI:0915”(physical association)	0.560
ZNF559	CABP5	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-1	ZNF559	psi-mi:“MI:0915”(physical association)	0.550
KRTAP10-3	ZNF559	psi-mi:“MI:0915”(physical association)	0.370
ZNF559	CARD10	psi-mi:“MI:0915”(physical association)	0.000
ZNF559	MDFI	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (22): ZNF559 (Two-hybrid), KRTAP4-2 (Two-hybrid), KRTAP10-1 (Two-hybrid), KRTAP10-5 (Two-hybrid), KRTAP10-3 (Two-hybrid), ZNF559 (Two-hybrid), ZNF559 (Two-hybrid), ZNF559 (Protein-RNA), KRTAP10-1 (Two-hybrid), KRTAP10-3 (Two-hybrid), KRTAP10-5 (Two-hybrid), MDFI (Two-hybrid), ZNF559 (Two-hybrid), ZNF559 (Two-hybrid), ZNF559 (Two-hybrid)

ESM2 similar proteins: A0JPL0, A6NK53, E7ETH6, E9Q8G5, O14628, P21506, P51508, Q09FC8, Q13360, Q2M218, Q2M3X9, Q2VY69, Q3KQV3, Q3SY52, Q4R882, Q5HY98, Q5REN4, Q5RES8, Q68DI1, Q6NX49, Q6P280, Q6PG37, Q6V9R5, Q6ZMW2, Q7Z340, Q86XU0, Q8IYI8, Q8N587, Q8N720, Q8N859, Q8NB42, Q8NDW4, Q8NEK5, Q8WXB4, Q96MR9, Q96MU6, Q96NG8, Q96NJ3, Q96SR6, Q9BR84

Diamond homologs: A0JPK3, A8MT65, C9JN71, E9QAG8, G3X9G7, O75820, P16373, P16374, P16415, P17017, P17024, P17025, P51815, P52737, Q08AG5, Q08ER8, Q0D2J5, Q15973, Q2M218, Q3KP31, Q3V080, Q494X3, Q4R4C7, Q5MYW4, Q5R9F0, Q5R9S5, Q5REI6, Q5REK1, Q68EA5, Q6P560, Q6P5C7, Q6ZQV5, Q7L945, Q86T29, Q8BGV5, Q8C6P8, Q8IYI8, Q8IZC7, Q8N7K0, Q8N972

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

110 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	107
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1259 predictions. Top by Δscore:

Variant	Effect	Δscore
19:9338492:A:G	acceptor_gain	1.0000
19:9338493:G:GG	acceptor_gain	0.9900
19:9324227:AGGTA:A	donor_loss	0.9800
19:9324228:GGT:G	donor_loss	0.9800
19:9324229:GT:G	donor_loss	0.9800
19:9324230:T:A	donor_loss	0.9800
19:9324693:A:G	acceptor_gain	0.9800
19:9338491:A:AG	acceptor_gain	0.9800
19:9339316:GTAG:G	donor_gain	0.9800
19:9341861:A:AG	acceptor_gain	0.9800
19:9324229:G:GG	donor_gain	0.9700
19:9330191:T:TA	donor_gain	0.9600
19:9330192:A:AA	donor_gain	0.9600
19:9341100:A:AG	acceptor_gain	0.9600
19:9341101:G:GG	acceptor_gain	0.9600
19:9341862:C:G	acceptor_gain	0.9600
19:9324226:GAG:G	donor_gain	0.9500
19:9324692:AAG:A	acceptor_gain	0.9500
19:9338489:TTAA:T	acceptor_loss	0.9500
19:9338490:TAA:T	acceptor_loss	0.9500
19:9338491:AAG:A	acceptor_loss	0.9500
19:9338492:A:T	acceptor_loss	0.9500
19:9338493:G:A	acceptor_loss	0.9500
19:9338493:G:GA	acceptor_loss	0.9500
19:9338493:GATC:G	acceptor_gain	0.9500
19:9341864:A:G	acceptor_gain	0.9500
19:9338490:TAAGA:T	acceptor_gain	0.9400
19:9341101:GATT:G	acceptor_gain	0.9400
19:9341860:CACA:C	acceptor_gain	0.9400
19:9341861:ACAA:A	acceptor_gain	0.9400

AlphaMissense

3586 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:9342535:T:C	F362L	0.997
19:9342537:T:A	F362L	0.997
19:9342537:T:G	F362L	0.997
19:9342703:T:C	F418L	0.996
19:9342705:C:A	F418L	0.996
19:9342705:C:G	F418L	0.996
19:9342787:T:C	F446L	0.996
19:9342789:T:A	F446L	0.996
19:9342789:T:G	F446L	0.996
19:9342871:T:C	F474L	0.996
19:9342873:C:A	F474L	0.996
19:9342873:C:G	F474L	0.996
19:9342955:T:C	F502L	0.996
19:9342957:T:A	F502L	0.996
19:9342957:T:G	F502L	0.996
19:9342451:T:C	F334L	0.995
19:9342453:C:A	F334L	0.995
19:9342453:C:G	F334L	0.995
19:9339226:T:C	F23L	0.993
19:9339228:C:A	F23L	0.993
19:9339228:C:G	F23L	0.993
19:9342485:G:C	R345P	0.993
19:9339227:T:C	F23S	0.992
19:9342619:T:C	F390L	0.992
19:9342621:T:A	F390L	0.992
19:9342621:T:G	F390L	0.992
19:9342890:T:C	L480P	0.992
19:9342554:T:C	L368P	0.991
19:9342732:T:A	H427Q	0.991
19:9342732:T:G	H427Q	0.991

dbSNP variants (sampled 300 via entrez): RS1000013275 (19:9325018 C>G), RS1000065651 (19:9323089 A>C), RS1000103492 (19:9327484 G>A), RS1000179104 (19:9344238 CAAAAA>C,CAAA,CAAAA,CAAAAAA), RS1000246152 (19:9341413 C>T), RS1000354761 (19:9323248 C>T), RS1000489581 (19:9345944 T>C), RS1000908640 (19:9327330 C>A,T), RS1000934049 (19:9332508 G>T), RS1000971401 (19:9335014 T>C), RS1000985846 (19:9342510 T>C), RS1001044385 (19:9337402 G>A,C), RS1001055645 (19:9340136 G>C), RS1001241477 (19:9328278 T>C), RS1001297618 (19:9335190 A>C,G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	2
Acrolein	affects cotreatment, increases expression, increases abundance	2
Ozone	increases expression, increases abundance, affects cotreatment	2
Cyclosporine	decreases expression, increases expression	2
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
bisphenol A	increases expression	1
terbufos	increases methylation	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
pentabromodiphenyl ether	decreases expression	1
rofecoxib	decreases expression	1
abrine	decreases expression	1
Temozolomide	increases expression	1
Decitabine	increases expression	1
Leflunomide	decreases expression	1
Air Pollutants	affects cotreatment, increases abundance, increases expression	1
Air Pollutants, Occupational	decreases expression	1
Allergens	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Dexamethasone	affects cotreatment, decreases expression	1
Fonofos	increases methylation	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Indomethacin	decreases expression, affects cotreatment	1
Methyl Methanesulfonate	increases expression	1
Nickel	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A8I9	SEES3-1V human ZNF559, clone1	Embryonic stem cell	Male
CVCL_A8J0	SEES3-1V human ZNF559, clone2	Embryonic stem cell	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder